Sotagliflozin improves outcomes in adults with and without p
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
SCORED trial included 10,584 participants with type 2 diabetes and CKD at risk for CVD. A new subgroup analyses at the ACC Scientific Session that looked at major adverse CV events stratified by history of CVD at baseline, which was defined as prior MI, stroke, coronary revascularization and/or peripheral vascular disease. Endpoints were total MACE, which comprised total CV death, nonfatal MI or nonfatal stroke; total fatal and nonfatal MI; and total fatal and nonfatal stroke.

In the sotagliflozin group, participants with a history of CVD (n = 5,144) saw a 21% decrease in MACE compared with those assigned placebo (HR = 0.79; 95% CI, 0.64-0.96; P = .02).

Participants assigned sotagliflozin with a history of CVD saw a 31% reduction in total MI (HR = 0.69; 95% CI, 0.51-0.95; P = .023), whereas those without a CVD history saw a 34% reduction in MI events (95% CI, 0.41-1.06; P = .088).

Those in the sotagliflozin group with and without baseline CVD also saw a 31% and 38% reduction in total stroke, respectively, compared with those assigned placebo.

The dual SGLT inhibitor sotagliflozin reduced total CV death, MI and stroke in adults with type 2 diabetes and chronic kidney disease both with and without prior CVD.